DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Bellevue Group AG

Bellevue Group AG lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 33.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,221,197 shares of the medical device company’s stock after acquiring an additional 306,604 shares during the period. DexCom comprises approximately 2.6% of Bellevue Group AG’s holdings, making the stock its 9th largest position. Bellevue Group AG owned approximately 0.31% of DexCom worth $169,380,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the company. Pacer Advisors Inc. raised its holdings in DexCom by 7.9% during the fourth quarter. Pacer Advisors Inc. now owns 55,174 shares of the medical device company’s stock valued at $6,847,000 after buying an additional 4,056 shares in the last quarter. Washington Trust Advisors Inc. grew its position in DexCom by 120.6% in the 4th quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after purchasing an additional 193 shares during the last quarter. Inscription Capital LLC bought a new position in DexCom during the fourth quarter valued at about $248,000. Caprock Group LLC lifted its position in shares of DexCom by 2.2% in the 4th quarter. Caprock Group LLC now owns 17,993 shares of the medical device company’s stock worth $2,233,000 after acquiring an additional 382 shares during the period. Finally, Gradient Investments LLC grew its holdings in shares of DexCom by 28.3% during the 4th quarter. Gradient Investments LLC now owns 152,839 shares of the medical device company’s stock worth $18,966,000 after purchasing an additional 33,742 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have commented on the stock. UBS Group cut their price target on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research note on Friday. Canaccord Genuity Group reiterated a “buy” rating and set a $145.00 target price on shares of DexCom in a research report on Tuesday, July 23rd. Raymond James raised their price target on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. JPMorgan Chase & Co. cut shares of DexCom from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $145.00 to $75.00 in a research report on Friday. Finally, Royal Bank of Canada decreased their price objective on DexCom from $165.00 to $145.00 and set an “outperform” rating on the stock in a research report on Friday. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus target price of $113.06.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 427 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $115.05, for a total value of $49,126.35. Following the completion of the sale, the executive vice president now directly owns 75,877 shares in the company, valued at $8,729,648.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Sadie Stern sold 427 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $115.05, for a total value of $49,126.35. Following the sale, the executive vice president now directly owns 75,877 shares in the company, valued at approximately $8,729,648.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bridgette P. Heller sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the completion of the transaction, the director now owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 4,112 shares of company stock worth $480,861. Corporate insiders own 0.30% of the company’s stock.

DexCom Stock Down 40.7 %

Shares of DXCM traded down $43.85 during mid-day trading on Friday, hitting $64.00. 53,914,127 shares of the company’s stock were exchanged, compared to its average volume of 2,657,874. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a 50-day simple moving average of $115.28 and a 200 day simple moving average of $123.76. The company has a market cap of $25.45 billion, a PE ratio of 41.29, a P/E/G ratio of 1.57 and a beta of 1.16. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a return on equity of 32.27% and a net margin of 16.95%. The business’s revenue was up 15.3% on a year-over-year basis. During the same period last year, the firm posted $0.34 earnings per share. On average, research analysts forecast that DexCom, Inc. will post 1.76 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.